UBS Group
KTTAW icon

UBS Group’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

UBS Group’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34
Closed – – 9812
2024
Q2 		$0 Hold
34
– – ﹤0.01% 9835
2024
Q1 		$0 Buy
+34
New – ﹤0.01% 9708
2023
Q4 		– Sell
-100
Closed -$1 – 9628
2023
Q3 		$1 Buy
+100
New +$2 ﹤0.01% 9377
2022
Q4 		– Sell
-1,849
Closed – – 10952
2022
Q3 		$0 Buy
1,849
+250
+16% +$25 ﹤0.01% 10649
2022
Q2 		$0 Buy
1,599
+799
+100% +$100 ﹤0.01% 10646
2022
Q1 		$0 Buy
+800
New +$191 ﹤0.01% 10598
2021
Q4 		– Sell
-45
Closed – – 10492
2021
Q3 		$0 Buy
+45
New +$35 ﹤0.01% 9823

Other funds holding KTTAW

KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group's KTTAW Position: Q3 2024 in Review

UBS Group sold out of Pasithea Therapeutics Warrants (KTTAW) in Q3 2024, closing a stake of 34 shares.

UBS Group first reported a position in KTTAW in Q3 2021 and held it in 7 quarters. The position peaked at $1 in Q3 2023. 5 funds tracked by Wall St. Rank hold KTTAW as of Q3 2024.

  • UBS Group reported no remaining Pasithea Therapeutics Warrants position as of Q3 2024 after selling out during the quarter.
  • UBS Group sold 34 Pasithea Therapeutics Warrants shares in Q3 2024.
  • UBS Group first reported a position in Pasithea Therapeutics Warrants in Q3 2021 and held it in 7 quarters.
  • UBS Group's Pasithea Therapeutics Warrants position peaked at $1 in Q3 2023.
  • 5 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.